Although the HER2-ultralow group also showed a trend towards higher grading compared to the HER2-low group in the overall cohort, this difference was no longer significant after stratifying the cases into HR+ breast cancer and TNBC subgroups for separate analysis.
← all excerpts
HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis.
1
—
—